Roy M Fleischmann, MD

Roy M Fleischmann, MD


Dr Fleischmann is Clinical Professor of Medicine at the University of Texas Southwestern Medical Center at Dallas, co-Director, Division of Rheumatology, Texas Health Presbyterian Medical Center and co- Medical Director of the Metroplex Clinical Research Center in Dallas. He is in the private practice of rheumatology in Dallas, TX. Dr. Fleischmann graduated from Stuyvesant High School in New York City and Columbia College in New York City. He received his MD from the State University of New York, Downstate Medical Center, and completed his residency in medicine at Mount Sinai Medical Center in New York City. His fellowship in rheumatology was completed at the College of Physicians and Surgeons of Columbia University, New York under the mentoring of Carwile Leroy. He is board certified in internal medicine with subspecialty certification in rheumatology. He was elected a Master of the American College of Rheumatology in 2010.

Although in private practice, Dr. Fleischmann has authored over 100 manuscripts, focusing on the management of rheumatoid arthritis, which have been published in peer-reviewed journals, and has authored over 200 abstracts, which have been presented at rheumatology meetings world-wide. For the past 35 years he has been an active teacher in the fellowship program of the University of Texas Southwestern Medical center. Dr Fleischmann has more than 30 years of experience as a clinical investigator. He has been a principal or co-principal investigator in over 750 clinical studies in the field of rheumatology, focusing on rheumatoid arthritis, but also in osteoarthritis, ankylosing spondylitis, gout, pain management, and osteoporosis. Dr. Fleischmann has helped design, implement and reported the results of studies on virtually every medication approved for use in the treatment of rheumatoid arthritis over the past 30 years. He has been an invited speaker at many international rheumatology meetings and symposia worldwide in which he has discussed the diagnosis and management of rheumatoid arthritis. Dr. Fleischmann was an early proponent of the aggressive treatment of rheumatoid arthritis and the importance of measuring disease activity in order to help guide treatment decisions.

Dr. Fleischmann has been president of the Texas Rheumatism Association and the Dallas–Fort Worth Rheumatism Association. He has served on the finance committee of the American College of Rheumatology and the Fundraising Committee of the Research and Education Foundation of the ACR. He has presented frequently at the ACR annual meeting and has conducted several Meet the Expert sessions. He is a reviewer for many peer-reviewed journals including Arthritis & Rheumatism, the Annals of Rheumatic Disease and the Journal of Rheumatology. He is an Associate Editor for Rheumatology (Oxford).

Publications in 2010

  1. van Vollenhoven, R, Emery, P, Bingham, CO, Keystone, E, Fleischmann, R, Furst, D, Macey,K, Sweetser, Marianne, Kelman, Ariella, Rao, R; Long-Term Safety of Patients Receiving Rituximab in Arthritis Clinical Trials. Journal of Rheumatology 2010; 37(3):558-567
  2. Fleischmann R; The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. Expert Opin. Biol. Ther. 2010 10(5):773-786
  3. Cohen S, Fleischmann R; Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010 22(3): 330-335
  4. Furst, D.E.; Keystone ,E.C.; Fleischmann, R.; Mease, P.; Breedveld, F.C.; Smolen, J.S.; Kalden, J.R.; Braun ,J.; Bresnihan ,B.; Burmester, G.R.; De,Benedetti  F.; Dorner,T.; Emery, P.; Gibofsky, A.; Kavanaugh ,A.; Kirkham, B.; Schiff ,M.H.; Sieper, J.; Singer ,N.; Van Riel ,P.L.; Weinblatt, M.E.; Weisman, M.H.; Winthrop ,K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010 69(Suppl 1):i2-i29
  5. Fleischmann R: The efficacy and safety of golimumab in the treatment of arthritis. Expert.Opin.Biol.Ther: 2010 10(7) 1131-1143
  6. Kavanaugh, A, Fleischmann, R, Wells, a; Update to Clinics of Rheumatic Diseases: New Biologic Agents. Update to Rheumatic Disease Clinics of North America; 2010: 4(2) 1-20
  7. Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A. Rituximab improved physical function and quality of life in patients with rheumatoid arthritis naive to methotrexate (IMAGE study). Arthritis Care Res; 2010:.[epub ahead of print. 12/08/2010]
  8. Kremer J, Blanco R, Brzosko M, Burgos-Vargas R,; Halland A, Vernon E, Ambs P, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: The LITHE study. Arthritis Rheum; 2010: [epub ahead of print. 11/19/2010]
  9. Weinblatt, M.E.; Bathon, J.M.; Kremer, J.M.; Fleischmann, R.M.; Schiff, M.H.; Martin, R.W.; Baumgartner, S.W.; Park, G.S.; Mancini ,E.L.; Genovese, M.C. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and long-standing rheumatoid arthritis. Arthritis Care Res 2010. [Epub ahead of print 10/18/2010]
Bookmark and Share